Key Highlights
- LivaNova shares were trading up 21.56% at $97.13, against a prior close of $79.90.
- Adjusted EPS of $1.23 beat estimates near $1.06 on Revenue of $393 million, up 10%.
- Full-year revenue growth guidance rose to 9% to 10% in constant currency.
- Adjusted EPS guidance rose to $4.40 to $4.50.
- Needham lifted its price target to $112 from $93.
Both Segments Grow at Double Digits
LivaNova (NASDAQ:LIVN) shares were trading up 21.56% at $97.13 on Wednesday, touching a new 52-week high of $99.38 on Volume near three times the average. Third-quarter adjusted EPS of $1.23 beat the consensus near $1.06, and revenue of $393 million rose 10%, ahead of estimates near $381 million.
Cardiopulmonary revenue of $225 million grew about 11%, and epilepsy sales also rose 11%, with US sales up 10% and the rest of the world up 14%. Adjusted gross Margin was 69%.
Guidance Lifted for the Second Time This Year
Management now expects 2026 revenue growth of 9% to 10% at constant currency, up from 8% to 9%, and adjusted EPS of $4.40 to $4.50, against a consensus near $4.36. Adjusted free Cash Flow guidance of $140 million to $160 million is unchanged. A GAAP charge tied to heater-cooler litigation held GAAP EPS to $0.11.
A new oxygenator Manufacturing line is now operating and, with a component Supply agreement, should drive double-digit output growth in 2027.
Epilepsy Pricing, Medicare Rates and Sleep Apnea Coding Add Support
Epilepsy growth reflects both volume and pricing running about twice the usual annual increase, helped by less discounting and Medicare reimbursement roughly 50% higher. A next-generation generator and digital platform are expected in 2027.
For obstructive sleep apnea, new Category 1 billing codes take effect on January 1, 2028, and Needham raised its target as the broader health rally after the midterms may also lift sentiment.
Valuation After a 21% Pop
The shares trade at 27.81 times trailing earnings, with a 52-week range of $48.82 to $99.38, so the stock has roughly doubled from its low. Next steps are fourth-quarter comparisons, oxygenator output and sleep apnea timing.






Please wait processing your request...